Epidemiological, clinical and immunological aspects of neuromyelitis optica (NMO)

Immunology and Microbiology

• Neuromyelitis Optica 100%
• Multiple Sclerosis 13%
• Central Nervous System 13%
• Prevalence 10%
• Aquaporin 4 Antibody 10%
• Allele 6%
• Clinically Isolated Syndrome 6%
• Immunogenetics 6%
• Autoantibodies 3%
• Genetic Background 3%
• Autoimmunity 3%
• Aquaporin 3%
• Parenchyma 3%
• Intravenous Immunoglobulin 3%
• Autoimmune Disease 3%
• Autoantigen 3%
• Immunoglobulin Blood Level 3%
• Blood Brain Barrier 3%
• Experimental Animal 3%
• Astrocyte 3%
• Inflammatory Cell 3%
• Immunoglobulin G 3%
• Cell Infiltration 3%
• Transverse Myelitis 3%
• Myelitis 3%
• Brain Stem 3%
• Cerebellum 3%
• Optic Neuritis 3%

Neuroscience

• Neuromyelitis Optica 100%
• Multiple Sclerosis 13%
• Central Nervous System 13%
• Aquaporin 4 Antibody 10%
• Demyelinating Disease 6%
• Cerebellum 3%
• Autoantibodies 3%
• Parenchyma 3%
• Autoimmune Disease 3%
• Blood Brain Barrier 3%
• Astrocyte 3%
• Intravenous Immunoglobulin 3%
• Brainstem 3%
• Optic Neuritis 3%
• Autoantigen 3%
• Intrathecal 3%
• Aquaporin 4 3%
• Cell Infiltration 3%
• Immunoglobulin G 3%
• Brain Lesion 3%
• Myelitis 3%
• Transverse Myelitis 3%
• Ependyma 3%
• Histopathology 3%

Pharmacology, Toxicology and Pharmaceutical Science

• Myelooptic Neuropathy 100%
• Multiple Sclerosis 13%
• Prevalence 10%
• Aquaporin 4 Antibody 10%
• Demyelinating Disease 6%
• Syndrome 3%
• Experimental Animal 3%
• Immunoglobulin G 3%
• Immunoglobulin 3%
• Human Study 3%
• Intrathecal 3%
• Autoimmune Disease 3%
• Autoantibodies 3%
• Clinical Study 3%
• Aquaporin 4 3%
• Nervous System Inflammation 3%
• Autoantigen 3%
• Optic Neuritis 3%
• Myelitis 3%
• Blood-Brain Barrier 3%
• Diseases 3%